ALKERMES | ALKS - Current Assets

Stock Price
32.26
Daily Change
0.35 1.10%
Monthly
-2.57%
Yearly
-9.18%
Q1 Forecast
30.94

ALKERMES reported $1.74B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 460.96M 80.75M Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
J&J USD 55.62B 1.01B Dec/2025
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 13.02M 2.53M Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Otsuka Holdings JPY 1.62T 113.12B Dec/2025
Ovoca Bio EUR 4.96M 2.06M Jun/2022
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025